These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 22151972)
1. Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favourable outcome during induction chemotherapy for acute leukaemias. Khalafallah A; Maiwald M; Hannan T; Abell S; Staker J; Supperamohan A Intern Med J; 2012 Feb; 42(2):131-6. PubMed ID: 22151972 [TBL] [Abstract][Full Text] [Related]
2. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia]. Andrade M A; Puga L B; Guerra C C; Molina E J; Capurro C M Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390 [TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671 [TBL] [Abstract][Full Text] [Related]
4. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251 [TBL] [Abstract][Full Text] [Related]
5. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327 [TBL] [Abstract][Full Text] [Related]
6. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770 [TBL] [Abstract][Full Text] [Related]
7. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Przepiorka D; Buadi FK; McClune B Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475 [TBL] [Abstract][Full Text] [Related]
8. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study. Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283 [TBL] [Abstract][Full Text] [Related]
9. [High risk febrile neutropenia in acute leukemia. The experience of a public hospital. National Program of Antineoplastic Drugs in Adult, Hospital del Salvador, 1991-2001]. Puga B; Puga I; Cabrera ME; Undurraga MS; Guerra C; Urrejola G; Toro P Rev Med Chil; 2003 Sep; 131(9):1023-30. PubMed ID: 14635589 [TBL] [Abstract][Full Text] [Related]
10. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases. Park JS; Kim DH; Choi CW; Jeong SH; Choi JH; Kim K; Kim SJ; Jung CW; Yang DH; Jang JH Acta Haematol; 2010; 124(2):92-7. PubMed ID: 20664196 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Goto N; Hara T; Tsurumi H; Ogawa K; Kitagawa J; Kanemura N; Kasahara S; Yamada T; Shimizu M; Nakamura M; Matsuura K; Moriwaki H Am J Hematol; 2010 Nov; 85(11):872-6. PubMed ID: 20882524 [TBL] [Abstract][Full Text] [Related]
16. Surveillance of the serum Candida antigen titer for initiation of antifungal therapy after post-remission chemotherapy in patients with acute leukemia. Iwasaki H; Misaki H; Nakamura T; Ueda T Int J Hematol; 2000 Apr; 71(3):266-72. PubMed ID: 10846834 [TBL] [Abstract][Full Text] [Related]
17. Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Gupta A; Singh M; Singh H; Kumar L; Sharma A; Bakhshi S; Raina V; Thulkar S Med Oncol; 2010 Dec; 27(4):1037-45. PubMed ID: 19830601 [TBL] [Abstract][Full Text] [Related]
18. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457 [TBL] [Abstract][Full Text] [Related]
19. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464 [TBL] [Abstract][Full Text] [Related]
20. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]